DelveInsight’s “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Smoking Cessation and Nicotine Addiction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Smoking Cessation and Nicotine Addiction Market Forecast
Some of the key facts of the Smoking Cessation and Nicotine Addiction Market Report:
-
The Smoking Cessation and Nicotine Addiction market size was valued ~USD 2,318 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In February 2025, Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company dedicated to developing and commercializing cytisinicline for smoking cessation and nicotine dependence, announced that the Data Safety Monitoring Committee (DSMC) has completed its second independent review of the ongoing ORCA-OL trial. This study evaluates the long-term exposure of the 3 mg cytisinicline dosing regimen in individuals who smoke cigarettes or vape nicotine.
-
In October 2024, ANANDA Scientific Inc., a research-driven biopharmaceutical company, in collaboration with the Semel Institute for Neuroscience at UCLA’s Geffen School of Medicine, has announced the launch of a clinical trial to assess Nantheia™ ATL5. This investigational drug, which combines cannabidiol (CBD) with ANANDA’s proprietary delivery technology, aims to evaluate CBD’s effectiveness in smoking cessation.
-
In 2023, the smoking cessation and nicotine addiction market was largest in the US among the 7MM, reaching approximately USD 1,472 million, while Germany had the smallest market size at USD 46 million, with expectations for growth by 2034.
-
The smoking cessation and nicotine addiction treatment market is expected to grow during the forecast period (2024-2034), driven by the emergence of new treatments such as cytisinicline, AXS-05, and NFL-101.
-
In 2023, the highest number of tobacco use cases was reported in EU4 and the UK, with approximately 63,953 thousand cases, followed by the US with around 50,886 thousand cases, and Japan with approximately 20,185 thousand cases. These figures are expected to decline in the US, EU4, the UK, and Japan by 2034.
-
In 2023, Germany reported the highest number of tobacco use cases among the EU4 and the UK, with around 18,101 thousand cases, followed by France with approximately 16,429 thousand cases. In contrast, the UK had the lowest number of tobacco use cases in both the EU4 and the UK, as well as across the 7MM, with 8,788 thousand cases.
-
Tobacco use is predominantly observed among males; our analysis shows that the number of males affected was greater than that of females. In 2023, approximately 59% of the prevalent tobacco use cases in the 7MM were among males, while around 41% were females.
-
Key Smoking Cessation and Nicotine Addiction Companies: Pfizer, GlaxoSmithKline, Cipla Ltd., Novartis, Takeda Pharma, McNeil AB, Revolymer plc, Imperial Tobacco Ltd., VMR Products, LLC., Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Currax Pharmaceuticals, Omeros Corporation, Axsome Therapeutics, McNeil AB, and others., and others
-
Key Smoking Cessation and Nicotine Addiction Therapies: CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline, NFL-101, EMB-001, CX-101, OMS-405, AXS-05, GSK598809, Nicotine Gum, and others
-
The Smoking Cessation and Nicotine Addiction epidemiology based on gender analyzed that, in the US the prevalence of tobacco use is higher in males than females
-
The Smoking Cessation and Nicotine Addiction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Smoking Cessation and Nicotine Addiction pipeline products will significantly revolutionize the Smoking Cessation and Nicotine Addiction market dynamics.
Smoking Cessation and Nicotine Addiction Overview
When tobacco use is repeated, a group of behavioural, cognitive, and physiological phenomena known as nicotine/tobacco dependence emerge. These phenomena typically include a strong desire to smoke, difficulty in controlling one's use, persistence in smoking despite negative effects, giving smoking a higher priority than other activities and obligations, increased tolerance, and occasionally a physical withdrawal state.
Get a Free sample for the Smoking Cessation and Nicotine Addiction Market Report:
https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Smoking Cessation and Nicotine Addiction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Smoking Cessation and Nicotine Addiction Epidemiology Segmentation:
The Smoking Cessation and Nicotine Addiction market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Smoking Cessation and Nicotine Addiction
-
Prevalent Cases of Smoking Cessation and Nicotine Addiction by severity
-
Gender-specific Prevalence of Smoking Cessation and Nicotine Addiction
-
Diagnosed Cases of Episodic and Chronic Smoking Cessation and Nicotine Addiction
Download the report to understand which factors are driving Smoking Cessation and Nicotine Addiction epidemiology trends @ Smoking Cessation and Nicotine Addiction Epidemiology Forecast
Smoking Cessation and Nicotine Addiction Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Smoking Cessation and Nicotine Addiction market or expected to get launched during the study period. The analysis covers Smoking Cessation and Nicotine Addiction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Smoking Cessation and Nicotine Addiction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Smoking Cessation and Nicotine Addiction Therapies and Key Companies
-
CHANTIX/ CHAMTIX (varenicline): Pfizer
-
ZYBAN (bupropion): GlaxoSmithKline
-
Cytisinicline: Achieve Life Sciences
-
NFL-101: NFL Biosciences SAS
-
EMB-001: Embera NeuroTherapeutics
-
CX-101: Currax Pharmaceuticals
-
OMS-405: Omeros Corporation
-
AXS-05: Axsome Therapeutics
Discover more about therapies set to grab major Smoking Cessation and Nicotine Addiction market share @ Smoking Cessation and Nicotine Addiction Treatment Market
Smoking Cessation and Nicotine Addiction Market Strengths
-
Advancements in treatment with emerging drugs that are expected to have novel MoAs and rapid onset of action
Smoking Cessation and Nicotine Addiction Market Opportunities
-
Lucrative opportunities are available to address unmet therapeutic needs in the smoking and nicotine deaddiction drug market as the existing pipeline remains insufficient
Scope of the Smoking Cessation and Nicotine Addiction Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Smoking Cessation and Nicotine Addiction Companies: Pfizer, GlaxoSmithKline, Cipla Ltd., Novartis, Takeda Pharma, McNeil AB, Revolymer plc, Imperial Tobacco Ltd., VMR Products, LLC., Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Currax Pharmaceuticals, Omeros Corporation, Axsome Therapeutics, McNeil AB, and others., and others
-
Key Smoking Cessation and Nicotine Addiction Therapies: CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline, NFL-101, EMB-001, CX-101, OMS-405, AXS-05, GSK598809, Nicotine Gum, and others
-
Smoking Cessation and Nicotine Addiction Therapeutic Assessment: Smoking Cessation and Nicotine Addiction current marketed and Smoking Cessation and Nicotine Addiction emerging therapies
-
Smoking Cessation and Nicotine Addiction Market Dynamics: Smoking Cessation and Nicotine Addiction market drivers and Smoking Cessation and Nicotine Addiction market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Smoking Cessation and Nicotine Addiction Unmet Needs, KOL’s views, Analyst’s views, Smoking Cessation and Nicotine Addiction Market Access and Reimbursement
To know more about Smoking Cessation and Nicotine Addiction companies working in the treatment market, visit @ Smoking Cessation and Nicotine Addiction Clinical Trials and Therapeutic Assessment
Table of Contents
1. Smoking Cessation and Nicotine Addiction Market Report Introduction
2. Executive Summary for Smoking Cessation and Nicotine Addiction
3. SWOT analysis of Smoking Cessation and Nicotine Addiction
4. Smoking Cessation and Nicotine Addiction Patient Share (%) Overview at a Glance
5. Smoking Cessation and Nicotine Addiction Market Overview at a Glance
6. Smoking Cessation and Nicotine Addiction Disease Background and Overview
7. Smoking Cessation and Nicotine Addiction Epidemiology and Patient Population
8. Country-Specific Patient Population of Smoking Cessation and Nicotine Addiction
9. Smoking Cessation and Nicotine Addiction Current Treatment and Medical Practices
10. Smoking Cessation and Nicotine Addiction Unmet Needs
11. Smoking Cessation and Nicotine Addiction Emerging Therapies
12. Smoking Cessation and Nicotine Addiction Market Outlook
13. Country-Wise Smoking Cessation and Nicotine Addiction Market Analysis (2020–2034)
14. Smoking Cessation and Nicotine Addiction Market Access and Reimbursement of Therapies
15. Smoking Cessation and Nicotine Addiction Market Drivers
16. Smoking Cessation and Nicotine Addiction Market Barriers
17. Smoking Cessation and Nicotine Addiction Appendix
18. Smoking Cessation and Nicotine Addiction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
